This week, the American College of Rheumatology and the National Psoriasis Foundation released a new treatment guideline for psoriatic arthritis (PsA) that contains evidence-based recommendations on caring for patients with this inflammatory disease.
This week, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) released a new treatment guideline for psoriatic arthritis (PsA) that contains evidence-based recommendations on caring for patients with this inflammatory disease.
The guideline was developed using Grading of Recommendations Assessment, Development and Evaluation methodology, and recommendations—many of which are conditional as they were based on low- to very low-quality evidence—were voted on by a panel of rheumatologists, dermatologists, health professionals, and patients.
Among key recommendations of the guideline is a conditional recommendation to use a treat-to-target approach for all patients with active PsA. “Treat-to-target is key, because it encompasses all clinical scenarios, rather than one particular clinical situation,” Jasvinder Singh, MD, MPH, a rheumatologist at the University of Alabama at Birmingham, said in a statement. “The available evidence suggests the irreversible joint damage, associated functional limitations, joint deformities and disability associated with PsA could possibly be avoided/delayed with optimal disease management using a targeted approach. A targeted approach can also improve pain, function and quality of life and social participation.”
Notably, the new guideline also includes a conditional recommendation to use anti—tumor necrosis factor (anti-TNF) therapies as first-line treatment. “The available evidence suggested that in the absence of certain conditions, many treatment-naïve patients would benefit from trying [an anti-TNF] biologic first,” said Dafna Gladman, MD, a rheumatology professor of medicine at the University of Toronto and NPF Medical Board member who served as a content expert during the guideline’s development. “This doesn’t hold true once other symptoms and comorbidities are present,” she added, so oral small-molecule drugs can continue to be an option for patients for whom a biologic is inappropriate.
The guideline also includes a strong recommendation for smoking cessation, particularly based on evidence that smoking reduces biologics’ efficacy (in addition to the fact that smoking is well understood to increase mortality, cancer, and heart and lung diseases).
Finally, the guideline makes a strong recommendation for using anti-TNF monoclonal antibodies instead of etanercept, an anti-TNF soluble receptor biologic, in patients who have concomitant inflammatory bowel disease (IBD). This recommendation, made on the basis of moderate-quality evidence that etanercept is less effective than other options in IBD, is accompanied by strong recommendations for patients with concomitant IBD to use an anti-TNF over an interleukin (IL)-17 inhibitor, and to use an IL-12/IL-23 inhibitor rather than an IL-17 inhibitor.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.